NAVA vs PSV Ventilation During Weaning From Mechanical Ventilation in Children After Liver Transplantation (NAVIGATE)

The Use of Neurally Adjusted Ventilator Assist Versus Pressure Support Ventilation durIng weaninG From Mechanical ventilAtion in pediaTric Patients After livEr Transplantation. A Physiologic Cross-over Controlled Trial. NAVIGATE Study

Liver transplantation is the treatment of choice for acute and chronic end-stage liver disease. Neurally Adjusted Ventilator Assist (NAVA) may be a feasible solution to guide the liberation from mechanical ventilation reducing asynchronies between patient and ventilator, and optimizing ventilator cycling. Cardiovascular and respiratory effects during NAVA ventilation are very limited after major abdominal surgery. The purpose of this application is to explore the efficacy of NAVA to reduce the asynchronies between the ventilator and pediatric patient admitted in Pediatric Intensive Care Unit (PICU) after major abdominal surgery, and the relationship between an optimal level of NAVA and cardiac and pulmonary function.

Study Overview

Detailed Description

Twelve pediatric patients underwent liver transplantation and admitted during postoperative period in PICU will be studied. They will be endotracheally intubated and spontaneously triggering the mechanical ventilator. In each patient enrolled a specially manufactured nasogastric tube will be inserted. This nasogastric tube is equipped with ten electrodes. The correct position of the nasogastric tube (and of electrodes) will be confirmed checking the good quality of Edi trace with the P waves displayed by the central electrodes on monitor of Servo I Ventilator (Maquet). All the patients will be ventilated using ventilators with NAVA option (Servo-I, Maquet Critical Care, Sweden). After a stabilization period in Pressure Support Ventilation (PSV) according with the attending physician, each patient will be studied for a duration of 2 hours, divided in three trials of 40-minutes (first 30 minutes to washout from the effects of previous ventilation mode and during the last 10 minutes the results will be recorded). Each patient will be randomized for ventilation mode sequence (PSV/NAVA/PSV or NAVA/PSV/NAVA). The patient tracings of flow, airway pressure, electrical activity of diaphragm for the patient-ventilator interaction analysis, blood gas analysis and cardiovascular parameters will be recorded during each trial.

Study Type

Interventional

Enrollment (Anticipated)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • RM
      • Rome, RM, Italy, 00165

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 10 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Liver recipients (from cadaveric or living donor)
  • Invasive Mechanical ventilation

Exclusion Criteria:

  • Neurological impairment
  • Neuromuscular, mitochondrial, metabolic, or chromosomal diseases with baby hypotonia
  • Lesions of medulla
  • Hemodynamic instability requiring inotropes/vasopressors (dopamine > 6 mcg/kg/min, norepinephrine, epinephrine, dobutamine, milrinone) or volume load.
  • Congenital cardiovascular disease
  • Patient extubated
  • Need of controlled mechanical ventilation
  • Intravenous infusion of benzodiazepines or propofol
  • Pneumonia, pneumothorax, massive pleural effusion
  • Patient placed on extracorporeal circuit
  • Contraindications to insert nasogastric tube
  • Not expected to survive beyond 24 hours
  • Parental/legal guardian refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: NAVA/PSV/NAVA
6 patients
Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
Active Comparator: PSV/NAVA/PSV
6 patients
Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asynchrony Index
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
Asynchrony Index (ratio between the number of asynchronous breathing events and the total respiratory rate, expressed as percentage) will be measured in the last 10 minutes of each ventilatory trial of 40 minutes.
last 10 minutes of each ventilatory trial, NAVA or PSV
Left and right ventricle function
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
Evaluation of left and right ventricular function variation during each ventilation mode. It will be measured by trans-thoracic echocardiogram in the last 10 minutes of each ventilatory trial of 40 minutes.
last 10 minutes of each ventilatory trial, NAVA or PSV

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
arterial partial pressure of oxygen (PaO2)
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
millimeters of mercury (mm Hg)
last 10 minutes of each ventilatory trial, NAVA or PSV
arterial partial pressure of carbon dioxide
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
mm Hg
last 10 minutes of each ventilatory trial, NAVA or PSV
oxygen index
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
{[mean airway pressure in centimeters of water × fraction of inspired oxygen × 100] ÷ PaO2 in mm Hg}
last 10 minutes of each ventilatory trial, NAVA or PSV
respiratory rate
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
breaths per minute
last 10 minutes of each ventilatory trial, NAVA or PSV
lactate
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
millimole/liter
last 10 minutes of each ventilatory trial, NAVA or PSV
heart rate
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
beats per minute (bpm)
last 10 minutes of each ventilatory trial, NAVA or PSV
cardiac index
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
{cardiac output [stroke volume (milliliter) x heart rate (bpm)] / body surface area (BSA; weight in kilograms and height in centimeters will be combined to report BSA in m^2)} in liters/minute/m^2
last 10 minutes of each ventilatory trial, NAVA or PSV
mean arterial pressure
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
mm Hg
last 10 minutes of each ventilatory trial, NAVA or PSV
central venous pressure
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
mm Hg
last 10 minutes of each ventilatory trial, NAVA or PSV
systemic vascular resistance
Time Frame: last 10 minutes of each ventilatory trial, NAVA or PSV
[(mean arterial pressure - central venous pressure) x 79.92 / cardiac index] in dynes/seconds/cm^-5
last 10 minutes of each ventilatory trial, NAVA or PSV

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fabrizio Chiusolo, MD, Bambino Gesù Hospital and Research Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Anticipated)

November 1, 2021

Study Completion (Anticipated)

January 30, 2022

Study Registration Dates

First Submitted

February 3, 2021

First Submitted That Met QC Criteria

March 8, 2021

First Posted (Actual)

March 11, 2021

Study Record Updates

Last Update Posted (Actual)

October 22, 2021

Last Update Submitted That Met QC Criteria

October 14, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Weaning From Mechanical Ventilation

Clinical Trials on Weaning from mechanical ventilation

3
Subscribe